MALDI Top-Down Sequencing (MALDI-TDS) delivers N- and C-terminal sequence readout for intact proteins or protein subunits within minutes. Leverage the novel neofleX™ MALDI-TDS workflow for verification of therapeutic antibodies, antigens and other protein expression products regarding sequence, terminal status and modifications and, thereby, enable instant decision making in strain development and production in biopharma or other branches of industry.
During this webinar, you will learn:
Who should attend:
Jan Hendrik Kobarg, Ph.D., Product Manager, MALDI-TOF, Bruker Daltonics, Bremen, Germany
Arndt Asperger, Ph.D., Senior Applications Scientist, Bruker Daltonics, Bremen, Germany
For Research Use Only. Not for use in clinical diagnostic procedures.